RxDoctor Payments DataLook up a doctor →

Sarah Mullins, MD

Family Medicine · Wilmington, DENPI 1942380092

Payments from drug & device makers

$36,359in general payments, 2019–2025

Across 698 payments — averaging $52.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$18K
  • Biohaven Pharmaceuticals, Inc.$8K
  • Amgen$964
  • Biohaven Pharmaceutical Holding Company Ltd.$962
  • Lilly USA, LLC$805
  • AstraZeneca$793
  • plus $7K from 49 others

What the payments were for

  • Consulting fees$1,5704%
  • Speaking & faculty fees$21,70060%
  • Travel & lodging$1,4754%
  • Food & beverage$11,59232%
  • Education$220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$36,359 in reported general payments places this provider in the 95th percentile of 352 family medicine providers in Delaware.

See all family medicine providers in Delaware

Medicare billing

Part B allowed, 2024
$279,380
Medicare patients
360
Services billed
5,701

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide34$41,019
JardianceEmpagliflozin22$38,486
OzempicSemaglutide23$34,981
XareltoRivaroxaban22$25,147
Xigduo XrDapaglifloz Propaned/Metformin13$19,692
EliquisApixaban11$19,376
Atorvastatin Calcium272$4,502
Breo ElliptaFluticasone/Vilanterol11$4,208
ShingrixVaricella-Zoster Ge/As01b/Pf12$2,666
Esomeprazole Magnesium24$2,008
Omeprazole90$1,885
Gabapentin61$1,771
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf20$1,409
Albuterol Sulfate HfaAlbuterol Sulfate34$1,333
Ventolin HfaAlbuterol Sulfate12$1,330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$805$41,01934 claims
Boehringer IngelheimJardiance$374$38,48622 claims
Novo NordiskOzempic$792$34,98123 claims
Johnson & JohnsonXarelto$323$25,14722 claims
PfizerEliquis$396$19,37611 claims
GSKBreo Ellipta, Shingrix$600$6,87423 claims
Almatica Pharma LLCSertraline Hcl$17$40471 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 352 family medicine providers in Delaware.

Other family medicine in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →